Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. The company also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
Follow-Up Questions
Roivant Sciences Ltd 的 CEO 是誰？
Mr. Matthew Gline 是 Roivant Sciences Ltd 的 Chief Executive Officer，自 2017 加入公司。
ROIV 股票的價格表現如何？
ROIV 的當前價格為 $17.95，在上個交易日 increased 了 3.99%。
Roivant Sciences Ltd 的主要業務主題或行業是什麼？
Roivant Sciences Ltd 屬於 Biotechnology 行業，該板塊是 Health Care
